
**UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549**

FORM 8-K

**CURRENT REPORT
Pursuant to Section 13 or 15(d) of the
Securities Exchange Act of 1934**

Date of Report (Date of earliest event reported): February 9, 2016

SEMLER SCIENTIFIC, INC.
(Exact name of registrant as specified in its charter)

Delaware
(State or other jurisdiction of incorporation)

001-36305
(Commission File Number)

26-1367393
(IRS Employer Identification No.)

**2330 NW Everett St.
Portland, Oregon**
(Address of principal executive offices)

97210
(Zip Code)

Registrant's telephone number, including area code: **(877) 774-4211**

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (*see* General Instruction A.2. below):

- Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
 - Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
 - Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
 - Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
-
-

Item 3.01. Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing.

As previously disclosed, Semler Scientific, Inc. (the “Company”) received a deficiency notice (the “Notice”), dated August 11, 2015, from the Nasdaq Stock Market (“NASDAQ”) notifying the Company that, as of June 30, 2015, the Company’s reported stockholders’ equity of \$1,698,000 did not meet the \$2,500,000 minimum required to maintain continued listing as set forth in NASDAQ Rule 5550(b)(1) (the “Rule”), and that as of August 10, 2015, the Company did not meet the alternative requirements of market value of listed securities or net income from continuing operations. In accordance with NASDAQ Rule 5810(c)(2), the Company was given 45 days from the date of the Notice, or until September 25, 2015, to submit to NASDAQ a plan to regain compliance with the continued listing requirements. On September 18, 2015, the Company submitted its plan to regain compliance with the continued listing requirements. By letter dated October 15, 2015, the Company was given until February 8, 2016, to regain compliance with the Rule.

On February 9, 2016, the Company received a Staff Determination Letter (the “Letter”) from NASDAQ notifying it that the Company had not regained compliance with the Rule. The Letter also stated that the Company’s securities would be scheduled for delisting and would be suspended at the opening of business on February 18, 2016, unless the Company requested an appeal of the decision to the Hearings Panel (the “Panel”) in accordance with the procedures set forth in the NASDAQ Listing Rule 5800 Series. Accordingly, the Company has requested a hearing before the Panel; this request has already been granted, and a hearing has been scheduled for March 31, 2016. Moreover, under the NASDAQ Listing Rules, and as has already been confirmed by the Company, this request for a hearing has automatically stayed the delisting of the Company’s common stock pending the issuance of a determination by the Panel.

There can be no assurances that the Company’s appeal will be successful in regaining compliance with the continued listing requirements and maintaining its listing of the Company’s common stock on the Nasdaq Capital Market.

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

SEMLER SCIENTIFIC, INC.

By: /s/ Douglas Murphy-Chutorian
Name: Douglas Murphy-Chutorian
Title: Chief Executive Officer

Date: February 16, 2016
